Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.

@article{Rasool2010SecretoryLP,
  title={Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.},
  author={Nabila Rasool and William Larochelle and Haihong Zhong and Gulshan Ara and Joshua Cohen and Elise C. Kohn},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 2},
  pages={600-9}
}
PURPOSE Ovarian cancer recurrence with the development of paclitaxel resistance is an obstacle to long-term survival. We showed that secretory leukocyte protease inhibitor (SLPI) is a survival factor for ovarian cancer. We hypothesize that SLPI may antagonize paclitaxel injury. EXPERIMENTAL DESIGN Differential SLPI induction in response to paclitaxel and… CONTINUE READING